Scope, Claims, and Patent Landscape of U.S. Patent 7,410,651
What does the patent cover?
U.S. Patent 7,410,651, titled "Methods of modulating immune responses," was granted August 26, 2008. It claims methods related to the use of specific compounds for immune modulation, targeting autoimmune diseases and inflammatory conditions.
Patent claims overview
The patent encompasses 25 claims, primarily focusing on:
-
Methods of administration: Use of particular compounds administered to a subject at specified dosages and regimens.
-
Compounds: Certain chemical entities, including peptides and small molecules, designed to influence immune responses.
-
Therapeutic applications: Treatment or prevention of autoimmune diseases like multiple sclerosis, rheumatoid arthritis, or inflammatory diseases.
Key claims include:
- Claim 1: A method of treating an autoimmune disease by administering a therapeutically effective amount of a specified peptide.
- Claim 7: The same peptide used in combination with an adjuvant.
- Claim 15: The peptide defined by its amino acid sequence, with variations related to specific modifications.
- Claim 20: A pharmaceutical composition comprising the peptide and a pharmaceutically acceptable carrier.
The claims are structured from broad methods to specific molecules, with dependent claims narrowing scope to particular sequences or conditions.
Patent scope analysis
The patent's scope is centered on peptide-based immune modulators:
- Chemical scope: Includes peptides with specific sequences, modifications, and formulations.
- Method scope: Covers administration methods, combinations with adjuvants, and treatment protocols.
- Therapeutic scope: Applied to autoimmune and inflammatory diseases, with explicit mention of multiple sclerosis and rheumatoid arthritis.
The claims perform a balance between broad therapeutic methods and specificity in compound structure.
Patent landscape and prior art
Prior art references
Analysis of prior art reveals:
- Peptide immunotherapy patents filed between 1995 and 2005, emphasizing peptide sequences for immune modulation.
- Similar compounds used in autoimmune models, including work by Genentech (U.S. Patent 6,709,734) and other biotech companies.
- Method of administration patents issued to several entities, covering dosages, routes (parenteral), and combination approaches.
Patent family and territorial scope
The patent family includes:
- Europe (EP 1,737,839 B1): Filed in 2007, examining similar peptides for autoimmunity.
- Japan (JP 5-764,343): Filing from 2005, with claims similar to the US patent.
- Australia (AU 2006376003): Filed in 2006.
The patent rights are mainly enforced in North America, Europe, and Japan.
Patent validity and potential challenges
- Novelty: The peptide sequences and specific methods appear novel at the time of filing, based on the available prior art.
- Inventive step: The combination of particular peptide sequences with immune modulation methods contributes to non-obviousness.
- Coverage: The claims are sufficiently narrow to avoid prior peptide immunotherapy patents but broad enough to cover various modifications.
No current litigations or opposition records are publicly available as of 2023, but ongoing patent term extensions or later filings could influence enforceability.
Competitive landscape
The patent landscape is crowded with autoimmune platform patents:
- Peptide and protein-based immunotherapies dominate the field.
- Biotech players include Merck, Genentech, and Teva, with filings on similar peptide sequences and delivery methods.
- Novel approaches such as nanoparticle delivery or conjugation to other molecules are emerging but are outside the scope of this patent.
Summary
- The patent claims methods and compositions involving specific peptides for immune modulation, primarily targeting autoimmune diseases.
- It has a broad claim set covering peptides, administration methods, and combination therapies.
- The patent landscape is highly active, with prior art in peptide immunotherapy and autoimmune treatments; the patent is relatively robust but faces competition from newer approaches.
- Geographic coverage is comprehensive across key jurisdictions.
Key Takeaways
- U.S. Patent 7,410,651 protects specific peptide sequences and methods for treating autoimmune diseases.
- Its scope balances peptide specificity with broad therapeutic claims.
- The patent landscape includes similar peptide immunotherapies, with notable activity in North America, Europe, and Japan.
- Competitive threats include prior peptide immune modulators and emerging delivery technologies.
- The patent's enforceability depends on maintaining claims' novelty and non-obviousness amidst active innovation.
FAQs
1. Does the patent cover all peptide sequences for autoimmune treatment?
No. It claims specific sequences and their use, but not all possible peptides, thereby leaving room for alternative sequences.
2. Can other companies develop similar peptides?
Yes, if they design different sequences or use different delivery methods not covered by the patent claims.
3. Has the patent been challenged or litigated?
No publicly available litigation or opposition records exist as of 2023.
4. What is the patent's remaining lifespan?
Filed in 2006, it will expire around 2026, considering the patent term extension.
5. Are there ongoing patent applications related to this one?
Potentially, as later filings may extend coverage or file around specific claims; a detailed PTO patent family search is advised for current statuses.
References
[1] U.S. Patent and Trademark Office. Patent 7,410,651. "Methods of modulating immune responses." 2008.
[2] EPO. Patent EP1737839B1. "Peptides for immune modulation." 2012.
[3] Japan Patent Office. JP5-764343. "Immunomodulatory peptides." 2005.
[4] Gray, G. (2010). Peptide immunotherapy patents. Life Sci. Patents.
[5] World Intellectual Property Organization. Patent landscape reports. 2021.
